FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2262252458> ?p ?o ?g. }

• W2262252458 endingPage "1457" @default.
• W2262252458 startingPage "1450" @default.
• W2262252458 abstract "To determine the highest dose of fluorouracil (5-FU) that could be safely administered with Eniluracil (776C85; Glaxo Wellcome Inc, Research Triangle Park, NC), an inactivator of dihydropyrimidine dehydrogenase (DPD), on a daily schedule for 5 days, and to define the toxicities of the combination and the pharmacokinetics of 5-FU when administered with 776C85.Patients with advanced solid tumors refractory to standard therapy were enrolled at two institutions. The study consisted of three periods designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of 776C85 alone (period 1); the effects of 776C85 on the pharmacokinetics of 5-FU (period 2); and the maximum-tolerated dose (MTD) of 5-FU, with or without leucovorin, that could be safely administered with 776C85 (period 3). Cohorts of at least three patients each received oral 776C85 alone at doses of 3.7 mg/m2/d, 18.5 mg/m2/d and 0.74 mg/m2/d. After a 14-day washout period, each patient then received 776C85 daily for 3 days, with a single intravenous (i.v.) bolus dose of 5-FU 10 mg/m2 on day 2. After a second washout period, patients were treated with 776C85 daily for 7 days and 5-FU i.v. bolus on days 2 through 6. The starting dose of 5-FU 10 mg/m2/d was escalated until the MTD was determined. After determination of the MTD of 5-FU given with 776C85, oral leucovorin 50 mg/d on days 2 through 6 was added to determine the MTD of 5-FU with leucovorin in the presence of 776C85. Near the completion of the study, additional cohorts of patients were treated with 776C85 at 50 mg/d and oral 5-FU with or without leucovorin.Sixty-five patients were enrolled onto the study and 60 were assessable for toxicity and response. Bone marrow suppression was the primary and dose-limiting toxicity of this regimen. Other toxicities included diarrhea, mucositis, anemia, anorexia, nausea, vomiting, and fatigue. 776C85 suppressed DPD activity in peripheral-blood mononuclear cells (PBMCs) by at least 90% for at least 24 hours at all dose levels tested. In the presence of 776C85, 5-FU half-life was prolonged, clearance was reduced, and the drug displayed linear pharmacokinetics. Recommended doses for further testing on a daily for 5-day schedule are 776C85 10 mg/d with i.v. 5-FU 25 mg/m2/d; 776C85 10 mg/d with i.v. 5-FU 20 mg/m2/d plus leucovorin 50 mg/d; 776C85 50 mg/d with 5-FU given orally at 15 mg/m2/d with leucovorin at 50 mg/d.5-FU can be safely administered with 776C85; however, the MTDs are considerably lower than those conventionally used, caused, at least in part, by marked alterations in 5-FU plasma pharmacokinetics." @default.
• W2262252458 created "2016-06-24" @default.
• W2262252458 creator A5014723395 @default.
• W2262252458 creator A5020638079 @default.
• W2262252458 creator A5023011880 @default.
• W2262252458 creator A5031299191 @default.
• W2262252458 creator A5064038800 @default.
• W2262252458 creator A5068268371 @default.
• W2262252458 creator A5071718298 @default.
• W2262252458 creator A5072308451 @default.
• W2262252458 creator A5072937045 @default.
• W2262252458 creator A5080900202 @default.
• W2262252458 date "1998-04-01" @default.
• W2262252458 modified "2023-09-25" @default.
• W2262252458 title "Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer." @default.
• W2262252458 cites W1540382842 @default.
• W2262252458 cites W1552036775 @default.
• W2262252458 cites W1580716972 @default.
• W2262252458 cites W1591466904 @default.
• W2262252458 cites W1828890888 @default.
• W2262252458 cites W1903289230 @default.
• W2262252458 cites W1916841389 @default.
• W2262252458 cites W1997551936 @default.
• W2262252458 cites W2117953362 @default.
• W2262252458 cites W2132895140 @default.
• W2262252458 cites W2151967297 @default.
• W2262252458 cites W2227311140 @default.
• W2262252458 cites W2460038169 @default.
• W2262252458 cites W2602544133 @default.
• W2262252458 cites W2413516421 @default.
• W2262252458 doi "https://doi.org/10.1200/jco.1998.16.4.1450" @default.
• W2262252458 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9552051" @default.
• W2262252458 hasPublicationYear "1998" @default.
• W2262252458 type Work @default.
• W2262252458 sameAs 2262252458 @default.
• W2262252458 citedByCount "104" @default.
• W2262252458 countsByYear W22622524582012 @default.
• W2262252458 countsByYear W22622524582013 @default.
• W2262252458 countsByYear W22622524582014 @default.
• W2262252458 countsByYear W22622524582015 @default.
• W2262252458 countsByYear W22622524582016 @default.
• W2262252458 countsByYear W22622524582017 @default.
• W2262252458 countsByYear W22622524582019 @default.
• W2262252458 countsByYear W22622524582020 @default.
• W2262252458 countsByYear W22622524582021 @default.
• W2262252458 countsByYear W22622524582022 @default.
• W2262252458 crossrefType "journal-article" @default.
• W2262252458 hasAuthorship W2262252458A5014723395 @default.
• W2262252458 hasAuthorship W2262252458A5020638079 @default.
• W2262252458 hasAuthorship W2262252458A5023011880 @default.
• W2262252458 hasAuthorship W2262252458A5031299191 @default.
• W2262252458 hasAuthorship W2262252458A5064038800 @default.
• W2262252458 hasAuthorship W2262252458A5068268371 @default.
• W2262252458 hasAuthorship W2262252458A5071718298 @default.
• W2262252458 hasAuthorship W2262252458A5072308451 @default.
• W2262252458 hasAuthorship W2262252458A5072937045 @default.
• W2262252458 hasAuthorship W2262252458A5080900202 @default.
• W2262252458 hasConcept C111113717 @default.
• W2262252458 hasConcept C112705442 @default.
• W2262252458 hasConcept C121608353 @default.
• W2262252458 hasConcept C123321153 @default.
• W2262252458 hasConcept C126322002 @default.
• W2262252458 hasConcept C126894567 @default.
• W2262252458 hasConcept C2778050828 @default.
• W2262252458 hasConcept C2780456651 @default.
• W2262252458 hasConcept C43376680 @default.
• W2262252458 hasConcept C71924100 @default.
• W2262252458 hasConcept C90924648 @default.
• W2262252458 hasConcept C98274493 @default.
• W2262252458 hasConceptScore W2262252458C111113717 @default.
• W2262252458 hasConceptScore W2262252458C112705442 @default.
• W2262252458 hasConceptScore W2262252458C121608353 @default.
• W2262252458 hasConceptScore W2262252458C123321153 @default.
• W2262252458 hasConceptScore W2262252458C126322002 @default.
• W2262252458 hasConceptScore W2262252458C126894567 @default.
• W2262252458 hasConceptScore W2262252458C2778050828 @default.
• W2262252458 hasConceptScore W2262252458C2780456651 @default.
• W2262252458 hasConceptScore W2262252458C43376680 @default.
• W2262252458 hasConceptScore W2262252458C71924100 @default.
• W2262252458 hasConceptScore W2262252458C90924648 @default.
• W2262252458 hasConceptScore W2262252458C98274493 @default.
• W2262252458 hasIssue "4" @default.
• W2262252458 hasLocation W22622524581 @default.
• W2262252458 hasLocation W22622524582 @default.
• W2262252458 hasOpenAccess W2262252458 @default.
• W2262252458 hasPrimaryLocation W22622524581 @default.
• W2262252458 hasRelatedWork W1972065231 @default.
• W2262252458 hasRelatedWork W1979719945 @default.
• W2262252458 hasRelatedWork W2051036097 @default.
• W2262252458 hasRelatedWork W2092754641 @default.
• W2262252458 hasRelatedWork W2162072376 @default.
• W2262252458 hasRelatedWork W2227061539 @default.
• W2262252458 hasRelatedWork W2262252458 @default.
• W2262252458 hasRelatedWork W2471520827 @default.
• W2262252458 hasRelatedWork W2594910449 @default.
• W2262252458 hasRelatedWork W2992709639 @default.
• W2262252458 hasVolume "16" @default.
• W2262252458 isParatext "false" @default.

• next